Overview

This trial is active, not recruiting.

Conditions gastric cancer, unspecified adult solid tumor, protocol specific
Treatments docetaxel, fluorouracil, oxaliplatin
Phase phase 1/phase 2
Sponsor Northwestern University
Collaborator National Cancer Institute (NCI)
Start date March 2005
End date December 2016
Trial size 58 participants
Trial identifier NCT00711243, NU 04I2, NU-0412, NU-948-006, P30CA060553, SANOFI - AVENTIS-NU0412, STU00006778

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when given with oxaliplatin and fluorouracil and to see how well they work in treating patients with metastatic or unresectable stomach cancer, gastroesophageal junction cancer, or other solid tumor.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Docetaxel 25 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
docetaxel
Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
fluorouracil
Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
oxaliplatin
Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
(Experimental)
Docetaxel 30 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
docetaxel
Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
fluorouracil
Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
oxaliplatin
Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
(Experimental)
Docetaxel 40 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
docetaxel
Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
fluorouracil
Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
oxaliplatin
Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
(Experimental)
Docetaxel 50 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
docetaxel
Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
fluorouracil
Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
oxaliplatin
Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
(Experimental)
Docetaxel 60 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
docetaxel
Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
fluorouracil
Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
oxaliplatin
Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel

Primary Outcomes

Measure
Maximum tolerated dose of docetaxel when given in combination with oxaliplatin and fluorouracil (Phase I)
time frame: After completion of 1 cycle of therapy (1 cycle = 14 days)
Response rate in patients with adenocarcinoma of the stomach or gastroesophageal junction (Phase II)
time frame: After 4 cycles of therapy (1 cycle = 14 days)

Secondary Outcomes

Measure
Dose-limiting toxicity of docetaxel when given in combination with oxaliplatin and fluorouracil
time frame: After 1 cycle of therapy (1 cycle = 14 days)
Frequency of CYP3A4, CYP3A5, and MDR polymorphisms and their impact on docetaxel toxicity
time frame: Blood sample cycle 1 day 1 and toxicity on day 1 of each cycle
Frequency of XRCC1 and ERCC2 polymorphisms and their impact on oxaliplatin toxicity
time frame: Blood sample cycle 1 day 1 and toxicity on day 1 of each cycle
Frequency of DPD and TSER polymorphisms and their impact on fluorouracil toxicity
time frame: Blood sample cycle 1 day 1 and toxicity on day 1 of each cycle
Toxicity profile
time frame: Day 1 of each cycle of therapy

Eligibility Criteria

Male or female participants from 18 years up to 120 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed metastatic or surgically unresectable solid tumor meeting 1 of the following criteria: - Any solid tumor (Phase I) - Adenocarcinoma of the stomach or gastroesophageal junction (Phase II) - Unidimensionally measurable disease by CT scan or MRI - No uncontrolled brain metastasis PATIENT CHARACTERISTICS: - ECOG performance status 0-1 - ANC ≥ 1,500/mm³ - Platelet count ≥ 100,000/mm³ - Hemoglobin ≥ 8.0 g/dL - Creatinine ≤ 1.5 times upper limit of normal (ULN) - Total bilirubin normal - Meets 1 of the following criteria: - Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times ULN - AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN - AP ≤ 5 times ULN AND AST or ALT normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for ≥ 3 months after completion of study therapy - No preexisting neuropathy - No concurrent uncontrolled illness or other condition that would preclude study compliance - No history of severe hypersensitivity reaction to docetaxel or to other drugs formulated with polysorbate 80 - No history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study PRIOR CONCURRENT THERAPY: - Recovered from prior therapy - More than 4 weeks since prior therapy (Phase I) - No prior oxaliplatin or taxanes (Phase I) - More than 4 weeks since prior radiotherapy (Phase I) - No more than two prior therapies for metastatic disease (Phase I) - No prior therapy for metastatic disease (Phase II) - At least 6 months since prior adjuvant therapy (given prior to the occurrence of metastatic disease) (Phase II) - Prior fluorouracil and concurrent radiotherapy for palliation of the primary tumor allowed provided metastatic disease is present outside the radiotherapy field (Phase II) - No prior radiotherapy to ≥ 30% of bone marrow - No other concurrent investigational agents

Additional Information

Official title A Phase I/II Study of Taxotere, Oxaliplatin, and 5- Fluorouracil
Principal investigator Mary Mulcahy, MD
Description OBJECTIVES: Primary - To establish the maximum tolerated dose of docetaxel when administered with oxaliplatin and fluorouracil in patients with metastatic or unresectable solid tumors. (Phase I) - To determine the response rate in patients with metastatic or unresectable adenocarcinoma of the stomach or gastroesophageal junction treated with this regimen. (Phase II) Secondary - To determine the dose limiting toxicity of this regimen in these patients. - To evaluate the frequency of CYP3A4, CYP3A5, and MDR polymorphisms and their impact on toxicity of docetaxel. - To evaluate the frequency of XRCC1 and ERCC2 polymorphisms and their impact on the toxicity of oxaliplatin. - To evaluate the frequency of DPD and TSER polymorphisms and their impact on the toxicity of fluorouracil. - To characterize the toxicity profile of this regimen in these patients. OUTLINE: This is a dose-escalation study of docetaxel. Patients receive docetaxel IV over 1 hour and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for at least 2 courses in the absence of disease progression, symptomatic tumor progression, or unacceptable toxicity. Patients undergo blood sample collection periodically for pharmacokinetic and pharmacogenomic correlative studies. Plasma concentrations of docetaxel are analyzed by reverse-phase high performance liquid chromatography and tandem mass spectrometry. Polymorphisms in CYP3A4/5, MDR, and other genes are analyzed by PCR. After completion of study therapy, patients are followed every 3 months. PROJECTED ACCRUAL: A total of 73 patients (30 for phase I and 43 for phase II) will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in September 2015.
Information provided to ClinicalTrials.gov by Northwestern University.